Research Slowly Resuming at L.A. VA Center

The $45-million research program at the Veterans Administration Greater Los Angeles Healthcare System (VAGLAHS) is slowly recovering after being abruptly shut down in March in an unprecedented sanction over regulations safeguarding patients in studies.1 "This might be the thing that wakes everybody up."--Stephen Pandol All 322 laboratory and animal studies, and more than 300 of the original 352 human clinical studies have been authorized to resume, leaving about 50 human studies in various s

Written byA. J. S. Rayl
| 5 min read

Register for free to listen to this article
Listen with Speechify
0:00
5:00
Share

The $45-million research program at the Veterans Administration Greater Los Angeles Healthcare System (VAGLAHS) is slowly recovering after being abruptly shut down in March in an unprecedented sanction over regulations safeguarding patients in studies.1


"This might be the thing that wakes everybody up."
All 322 laboratory and animal studies, and more than 300 of the original 352 human clinical studies have been authorized to resume, leaving about 50 human studies in various stages of review. In addition, 29 new human studies have been approved since the shutdown. "It's quite a laborious process putting them through this review," says acting research director Marguerite Hays, who is on leave from the Palo Alto, Calif. VA medical center.

--Stephen Pandol

"The difficulty has been that it takes an awful lot of work to re-review all the protocols as though they have never been reviewed before," says John R. Feussner, VA chief of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies